Across TCGA pan-cancer cohorts, LY6E-DT RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated LY6E-DT data layer.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher LY6E-DT RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated LY6E-DT expression acts as an unfavorable survival marker, although some lineages such as KIRC and ACC show a favorable association.
KIRC, KIRP, and ACC are the cancer types where LY6E-DT RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.